Behavioral Health Business June 20, 2024
By the time the pandemic broke out, interest in digital therapeutics (DTx) had reached an all-time high. Investors, pharma giants and even health systems have poured billions into the products promising to change medicine.
A few of the pioneers in the space, including Pear Therapeutics, which has several addiction therapeutics, and Akili, which is focused on ADHD therapeutics, got wrapped up in the SPAC craze of 2021 and 2022 and went public.
While digital therapeutics may still have their day, some of the industry’s forerunners have had major stumbles. That makes it worth considering whether there is still a future for the DTx industry – a role for DTx to play in behavioral health care.
Digital therapeutics refers to evidence-based...
Today's Sponsors
Today's Sponsor